Cargando…

Novel CSF biomarkers to discriminate FTLD and its pathological subtypes

OBJECTIVE: Frontotemporal lobar degeneration (FTLD) is the second most prevalent dementia in young patients and is characterized by the presence of two main protein aggregates in the brain, tau (FTLD‐Tau) or TDP43 (FTLD‐TDP), which likely require distinct pharmacological therapy. However, specific d...

Descripción completa

Detalles Bibliográficos
Autores principales:	del Campo, Marta, Galimberti, Daniela, Elias, Naura, Boonkamp, Lynn, Pijnenburg, Yolande A., van Swieten, John C., Watts, Kelly, Paciotti, Silvia, Beccari, Tommaso, Hu, William, Teunissen, Charlotte E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186934/ https://www.ncbi.nlm.nih.gov/pubmed/30349851 http://dx.doi.org/10.1002/acn3.629

Ejemplares similares

Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies
por: del Campo, Marta, et al.
Publicado: (2021)

Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics
por: Teunissen, Charlotte E., et al.
Publicado: (2016)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

Movement disorders are linked to TDP-43 burden in the substantia nigra of FTLD-TDP brain donors
por: Fiondella, Luigi, et al.
Publicado: (2023)

Discovery of novel CSF biomarkers to predict progression in dementia using machine learning
por: Gogishvili, Dea, et al.
Publicado: (2023)

Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43
por: Tan, Rachel H, et al.
Publicado: (2013)

Neuronal VCP loss of function recapitulates FTLD-TDP pathology
por: Wani, Abubakar, et al.
Publicado: (2021)

CSF proteomics in autosomal dominant Alzheimer’s disease highlights parallels with sporadic disease
por: van der Ende, Emma L, et al.
Publicado: (2023)

C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts
por: Costa, Beatrice, et al.
Publicado: (2020)

Detecting clinical change with the CDR‐FTLD: differences between FTLD and AD dementia
por: Mioshi, Eneida, et al.
Publicado: (2016)

Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders
por: Vijverberg, Everard G.B., et al.
Publicado: (2017)

Heterogeneous nuclear ribonucleoproteins R and Q accumulate in pathological inclusions in FTLD-FUS
por: Gittings, Lauren M., et al.
Publicado: (2019)

Regional and hemispheric susceptibility of the temporal lobe to FTLD-TDP type C pathology
por: Borghesani, V., et al.
Publicado: (2020)

Frontotemporal Dementia: Correlations Between Psychiatric Symptoms and Pathology
por: Scarioni, Marta, et al.
Publicado: (2020)

Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson’s Disease
por: Paciotti, Silvia, et al.
Publicado: (2020)

New CSF biomarkers on the block
por: Teunissen, Charlotte E, et al.
Publicado: (2016)

A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias
por: Bolsewig, Katharina, et al.
Publicado: (2022)

Topography of FUS pathology distinguishes late-onset BIBD from aFTLD-U
por: Lee, Edward B, et al.
Publicado: (2013)

Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD–ALS spectrum disorders
por: Janssens, Jonathan, et al.
Publicado: (2013)

Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD
por: Wood, Alistair, et al.
Publicado: (2021)

NUP62 localizes to ALS/FTLD pathological assemblies and contributes to TDP-43 insolubility
por: Gleixner, Amanda M., et al.
Publicado: (2022)

FTLD‐TDP assemblies seed neoaggregates with subtype‐specific features via a prion‐like cascade
por: De Rossi, Pierre, et al.
Publicado: (2021)

Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias
por: Hanes, Jozef, et al.
Publicado: (2020)

CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease
por: del Campo, Marta, et al.
Publicado: (2023)

Loss of TMEM106B potentiates lysosomal and FTLD‐like pathology in progranulin‐deficient mice
por: Werner, Georg, et al.
Publicado: (2020)

Importance of Functional Loss of FUS in FTLD/ALS
por: Ishigaki, Shinsuke, et al.
Publicado: (2018)

The FUS about SFPQ in FTLD spectrum disorders
por: Patani, Rickie
Publicado: (2020)

Distinct and shared neuropsychiatric phenotypes in FTLD-tauopathies
por: Keszycki, Rachel, et al.
Publicado: (2023)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
por: Vromen, Eleonora M., et al.
Publicado: (2022)

New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia
por: del Campo, Marta, et al.
Publicado: (2022)

CSF or serum neurofilament light added to α‐Synuclein panel discriminates Parkinson's from controls
por: Oosterveld, Linda P., et al.
Publicado: (2019)

Biomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study
por: Vromen, Eleonora M, et al.
Publicado: (2022)

Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum
por: Meeter, Lieke H.H., et al.
Publicado: (2018)

Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer’s disease
por: Lewczuk, Piotr, et al.
Publicado: (2018)

Inside out: the role of nucleocytoplasmic transport in ALS and FTLD
por: Boeynaems, Steven, et al.
Publicado: (2016)

Disease-modifying effects of metabolic perturbations in ALS/FTLD
por: Jawaid, Ali, et al.
Publicado: (2018)

β-Arrestin2 arrests the clearance of tau in FTLD
por: Thathiah, Amantha
Publicado: (2020)

Tau immunotherapy is associated with glial responses in FTLD-tau
por: Kim, Boram, et al.
Publicado: (2021)

Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U
por: Tsai, Kuen-Jer, et al.
Publicado: (2010)

Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics
por: van der Ende, Emma L., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8scac9v37ihefbe8jvapfpqu2t